Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 18/20 | 0.71 |
| ▸ | PPARA | Q07869 | 17/20 | 0.71 |
| ▸ | PPARD | Q03181 | 3/20 | 0.45 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6275895 | 0.93 | PPARG (0.73) | PPARGPPARAPPARDCACNA1B | |
| SCHEMBL6281840 | 0.91 | PPARG (0.70) | PPARGPPARAPPARD | |
| SCHEMBL5342984 | 0.86 | PPARA (0.83) | PPARGPPARAPPARD | |
| SCHEMBL4823006 | 0.86 | PPARA (0.83) | PPARGPPARAPPARD | |
| SCHEMBL6002523 | 0.85 | PPARG (0.81) | PPARGPPARAPPARD | |
| Ragaglitazar SCHEMBL29369224 | 0.83 | PPARA (1.00) | PPARGPPARAPPARD | |
| Ragaglitazar SCHEMBL4822459 | 0.83 | PPARA (1.00) | PPARGPPARAPPARD | |
| Ragaglitazar SCHEMBL676872 | 0.83 | PPARA (1.00) | PPARGPPARAPPARD | |
| Ragaglitazar SCHEMBL682732 | 0.83 | PPARA (1.00) | PPARGPPARAPPARD | |
| Ragaglitazar SCHEMBL6280340 | 0.83 | PPARG (0.83) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6897199-B2 | Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-05-24 | — | — | US | claimed |
| US-20020169146-A1 | Pharmaceutically acceptable salts of tricyclic compounds | DR. REDDY'S LABORATORIES LTD. | 2002-11-14 | — | — | US | claimed |
| US-6897199-B2 | Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-05-24 | — | — | US | disclosed |
| US-20020169146-A1 | Pharmaceutically acceptable salts of tricyclic compounds | DR. REDDY'S LABORATORIES LTD. | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169146-A1 | Pharmaceutically acceptable salts of tricyclic compounds | CYP3A43, ABCG2, SLCO1B3 | PPARG 333/4885PPARA 1364/4885PPARD 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.